PEPTIDE BASED VACCINE FOR PRIMATE MODEL OF AIDS

Information

  • Research Project
  • 2887026
  • ApplicationId
    2887026
  • Core Project Number
    R44AI038081
  • Full Project Number
    5R44AI038081-03
  • Serial Number
    38081
  • FOA Number
  • Sub Project Id
  • Project Start Date
    8/1/1996 - 28 years ago
  • Project End Date
    9/29/2000 - 24 years ago
  • Program Officer Name
    BRADAC, JAMES A.
  • Budget Start Date
    9/30/1999 - 25 years ago
  • Budget End Date
    9/29/2000 - 24 years ago
  • Fiscal Year
    1999
  • Support Year
    3
  • Suffix
  • Award Notice Date
    9/13/1999 - 25 years ago
Organizations

PEPTIDE BASED VACCINE FOR PRIMATE MODEL OF AIDS

Specific Aims: Simian immunodeficiency virus (SIV) infection of macaques provides the best non- human primate model for studying AIDS. We will utilize the SIV/macaque model to determine whether the generation of AIDS virus-specific cytotoxic T lymphocytes (CTLs) and helper T lymphocytes (HTL) can protect against, or alter the course of AIDS virus infection in vivo. Specifically, we will use in vitro binding and immunogenicity assays to identify multiple CTL and HTL epitopes derived from the SIV Mac 251, and restricted by Mamu A*01 and defined DRB alleles Lipopeptides and cDNA minigenes will be utilized to deliver epitopes the identified to rhesus macaques expressing the appropriate MHC types. Challenge studies will examine the prophylactic efficancy of immunization with these constructs, and we correlate each outcome with elicitation of specific HTL responses, CTL responses and potential appearance of viral escape mutants. PROPOSED COMMERCIAL APPLICATION: The overall focus of our research is to develop a vaccine for prevention and treatment HIV and AIDS infection. The proposed research will develop an adequate system for testing the multi epitope approach to immunotherapy in non-human primates. SIV infection of macaques provides the best non-human primate model for studying AIDS.

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    R44
  • Administering IC
    AI
  • Application Type
    5
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    856
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    ZRG5
  • Study Section Name
  • Organization Name
    IDM PHARMA, INC.
  • Organization Department
  • Organization DUNS
    018540968
  • Organization City
    IRVINE
  • Organization State
    CA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    926181666
  • Organization District
    UNITED STATES